These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
157 related items for PubMed ID: 11096017
1. Osteonecrosis complicating highly active antiretroviral therapy in patients infected with human immunodeficiency virus. Monier P, McKown K, Bronze MS. Clin Infect Dis; 2000 Dec; 31(6):1488-92. PubMed ID: 11096017 [Abstract] [Full Text] [Related]
2. Osteonecrosis in patients with human immunodeficiency virus type 1 infection in Taiwan. Ho YC, Shih TT, Lin YH, Hsiao CF, Chen MY, Hsieh SM, Sheng WH, Sun HY, Hung CC, Chang SC. Jpn J Infect Dis; 2007 Nov; 60(6):382-6. PubMed ID: 18032839 [Abstract] [Full Text] [Related]
4. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy. Van Vaerenbergh K. Verh K Acad Geneeskd Belg; 2001 Nov; 63(5):447-73. PubMed ID: 11813503 [Abstract] [Full Text] [Related]
8. Predictors of sustained response to therapy resumption after treatment interruption in HIV-infected patients failing antiretroviral therapy. Gianotti N, Soria A, Galli L, Castagna A, Cernuschi M, Hasson H, Lazzarin A. J Med Virol; 2004 Feb; 72(2):181-6. PubMed ID: 14695657 [Abstract] [Full Text] [Related]
10. Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings. Bedell R, Heath KV, Hogg RS, Wood E, Press N, Yip B, O'Shaughnessy MV, Montaner JS. Antivir Ther; 2003 Oct; 8(5):379-84. PubMed ID: 14640384 [Abstract] [Full Text] [Related]
11. Rapid effect of interleukin-2 therapy in human immunodeficiency virus-infected patients whose CD4 cell counts increase only slightly in response to combined antiretroviral treatment. David D, Naït-Ighil L, Dupont B, Maral J, Gachot B, Thèze J. J Infect Dis; 2001 Mar 01; 183(5):730-5. PubMed ID: 11181149 [Abstract] [Full Text] [Related]
12. Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes. Pariente N, Pernas M, de la Rosa R, Gómez-Mariano G, Fernández G, Rubio A, López M, Benito JM, López-Galíndez C, Leal M, Domingo E, Martinez MA, Mas A. J Med Virol; 2004 Jul 01; 73(3):350-61. PubMed ID: 15170628 [Abstract] [Full Text] [Related]
13. Long-term outcomes among antiretroviral-naive human immunodeficiency virus-infected patients with small increases in CD4+ cell counts after successful virologic suppression. Dronda F, Moreno S, Moreno A, Casado JL, Pérez-Elías MJ, Antela A. Clin Infect Dis; 2002 Oct 15; 35(8):1005-9. PubMed ID: 12355389 [Abstract] [Full Text] [Related]
14. Bone disorders in human immunodeficiency virus infection. Glesby MJ. Clin Infect Dis; 2003 Oct 15; 37 Suppl 2():S91-5. PubMed ID: 12942380 [Abstract] [Full Text] [Related]
15. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)]. Panel de expertos de Gesida y Plan Nacional sobre el Sida. Enferm Infecc Microbiol Clin; 2009 Apr 15; 27(4):222-35. PubMed ID: 19246124 [Abstract] [Full Text] [Related]
16. Improvement of symptomatic human immunodeficiency virus-related lymphoid interstitial pneumonia in patients receiving highly active antiretroviral therapy. Dufour V, Wislez M, Bergot E, Mayaud C, Cadranel J. Clin Infect Dis; 2003 May 15; 36(10):e127-30. PubMed ID: 12746792 [Abstract] [Full Text] [Related]
17. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients. Rodes B, García F, Gutierrez C, Martinez-Picado J, Aguilera A, Saumoy M, Vallejo A, Domingo P, Dalmau D, Ribas MA, Blanco JL, Pedreira J, Perez-Elias MJ, Leal M, de Mendoza C, Soriano V, Red de Investigación en SIDA. J Med Virol; 2005 Sep 15; 77(1):23-8. PubMed ID: 16032728 [Abstract] [Full Text] [Related]
18. Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis. Sungkanuparph S, Overton ET, Seyfried W, Groger RK, Fraser VJ, Powderly WG. Clin Infect Dis; 2005 Nov 01; 41(9):1326-32. PubMed ID: 16206110 [Abstract] [Full Text] [Related]
19. Improved outcomes with earlier initiation of highly active antiretroviral therapy among human immunodeficiency virus-infected patients who achieve durable virologic suppression: longer follow-up of an observational cohort study. Sterling TR, Chaisson RE, Keruly J, Moore RD. J Infect Dis; 2003 Dec 01; 188(11):1659-65. PubMed ID: 14639536 [Abstract] [Full Text] [Related]
20. Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy. Smith CJ, Sabin CA, Youle MS, Kinloch-de Loes S, Lampe FC, Madge S, Cropley I, Johnson MA, Phillips AN. J Infect Dis; 2004 Nov 15; 190(10):1860-8. PubMed ID: 15499544 [Abstract] [Full Text] [Related] Page: [Next] [New Search]